{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:07:38Z","timestamp":1784934458738,"version":"3.55.0"},"reference-count":80,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Celltrion, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Perianal fistulizing Crohn\u2019s disease (pfCD), a frequent and serious manifestation of Crohn\u2019s disease (CD), is characterized by perianal inflammation and fistula formation and severely impacts patient quality of life. Due to its complex and progressive nature, pfCD requires effective, multidisciplinary management combining both medical and surgical approaches. Infliximab (IFX), a tumor necrosis factor inhibitor, remains the preferred treatment of pfCD. It is recommended in several international clinical guidelines and supported by extensive clinical evidence demonstrating its efficacy and safety in this patient population. Higher IFX serum concentrations have been associated with improved clinical outcomes in CD, reinforcing the need for optimized therapeutic strategies. Subcutaneous (SC) IFX is a more recently available alternative to intravenous (IV) IFX, offering comparable efficacy and safety in patients with CD and greater convenience through self-administration. Although SC IFX has not been evaluated in randomized controlled trials specifically in patients with pfCD, its use has been explored in real-world prospective and retrospective studies. SC IFX treatment in patients with pfCD has achieved sustained clinical and radiological remission with low recurrence rates, and high treatment persistence was observed without new safety issues, supporting its potential as a therapeutic option for pfCD. SC IFX may provide additional advantages over IV IFX, including reduced treatment burden for patients. However, evidence from prospective studies specifically investigating SC IFX in pfCD remains limited. Further research, particularly studies evaluating pfCD-specific clinical and radiological outcomes, are needed to better define the role of SC IFX in pfCD treatment. In summary, this review underscores the well-established role of IV IFX in pfCD, highlights the emerging evidence supporting SC IFX, and identifies key knowledge gaps that require further investigation to inform future treatment strategies in pfCD.<\/jats:p>","DOI":"10.1177\/17562848261461042","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:27:53Z","timestamp":1784651273000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn\u2019s disease: current evidence and emerging roles"],"prefix":"10.1177","volume":"19","author":[{"given":"Axel","family":"Dignass","sequence":"first","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reenaers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU Li\u00e8ge, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital Estaing of Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Porto Medical School, University of Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Gastroenterology Department at CHRU de Besan\u00e7on, UMR Inserm 1098, Universit\u00e9 Marie et Louis Pasteur, Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2769-333X","authenticated-orcid":false,"given":"Soyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6186-3571","authenticated-orcid":false,"given":"Meoung Jun","family":"Park","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY 10029-6574, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_3_4_5_2","first-page":"33","article-title":"Management of complex perianal Crohn\u2019s disease","volume":"30","author":"Aguilera-Castro L","year":"2017","unstructured":"Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, et al. Management of complex perianal Crohn\u2019s disease. Ann Gastroenterol 2017; 30: 33\u201344.","journal-title":"Ann Gastroenterol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad008"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.104"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32362"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002326"},{"key":"e_1_3_4_10_2","first-page":"1","article-title":"Getting to the bottom of it: essential insights into perianal Crohn\u2019s disease","volume":"0","author":"Shakweh E","year":"2026","unstructured":"Shakweh E, Hanna L, Anand E, et al. Getting to the bottom of it: essential insights into perianal Crohn\u2019s disease. Frontline Gastroenterol 2026; 0: 1\u201313.","journal-title":"Frontline Gastroenterol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003906"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae089"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07491-y"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101489"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab198"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab398"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314918"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003465"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.047"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00088-7"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-011-0759-4"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14016"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0018"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_3_4_28_2","unstructured":"European Medicines Agency. Remsima\u2014summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf (2020 accessed November 2025)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S240593"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.006"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf060"},{"key":"e_1_3_4_32_2","unstructured":"Food and Drug Administration. Zymfentra\u2014prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761358Orig1s001lbl.pdf (2024 accessed November 2025)."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.042"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21940"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.10.022"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.053"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06398-w"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003755"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(25)04450-6"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(25)04436-1"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.011"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251326471"},{"key":"e_1_3_4_46_2","article-title":"PMO-28 Efficacy of subcutaneous infliximab in perianal Crohn\u2019s disease","volume":"70","author":"Smith PJ","year":"2021","unstructured":"Smith PJ, Storey D, Gregg B, et al. PMO-28 Efficacy of subcutaneous infliximab in perianal Crohn\u2019s disease. Gut 2021; 70: A91\u2013A92.","journal-title":"Gut"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac053"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092130"},{"key":"e_1_3_4_49_2","first-page":"922","article-title":"LB02 A retrospective cohort study to compare the efficacy, pharmacokinetics and safety of subcutaneous (SC) and intravenous (IV) infliximab in the treatment of inflammatory bowel disease","volume":"11","author":"Mahmood T","year":"2023","unstructured":"Mahmood T, Ibarra A, Lindsay J. LB02 A retrospective cohort study to compare the efficacy, pharmacokinetics and safety of subcutaneous (SC) and intravenous (IV) infliximab in the treatment of inflammatory bowel disease. United Eur Gastroenterol J 2023; 11: 922\u2013923.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000002228"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae059"},{"key":"e_1_3_4_52_2","unstructured":"Australian New Zealand Clinical Trials Registry. ISOMETRIC CD (efficacy of subcutaneous infliximab maintenance therapy in perianal Crohn\u2019s disease) https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=384376 (2022 accessed November 2025)."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001111"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13970"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i23.2597"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1600014"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-024-02953-z"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001561"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0056"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae127"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08876-5"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251333516"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad188"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18354"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09210-9"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.1316"},{"key":"e_1_3_4_67_2","first-page":"440","article-title":"Subcutaneous infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in inflammatory bowel disease: post hoc analysis of LIBERTY-UC study and LIBERTY-CD study","volume":"11","author":"Danese S","year":"2023","unstructured":"Danese S, Colombel JF, Hanauer S, et al. Subcutaneous infliximab (CT-P13 SC) dose escalation as an option for managing the loss of response in inflammatory bowel disease: post hoc analysis of LIBERTY-UC study and LIBERTY-CD study. United Eur Gastroenterol J 2023; 11: 440\u2013442.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_68_2","first-page":"131","article-title":"Two year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy as an option for managing loss of response in inflammatory bowel disease\u2014from LIBERTY-UC and LIBERTY-CD study","volume":"12","author":"Schreiber S","year":"2024","unstructured":"Schreiber S, Colombel J-F, Hanauer S, et al. Two year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy as an option for managing loss of response in inflammatory bowel disease\u2014from LIBERTY-UC and LIBERTY-CD study. United Eur Gastroenterol J 2024; 12: 131.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21888"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2024.11.004"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-014-0075-y"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01162-6"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04727-3"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75693-7"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0842"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.02.009"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-11029-3"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003838"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.1362"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.1159"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308099"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001260"},{"key":"e_1_3_4_83_2","first-page":"1092","article-title":"Tissue drug levels are significantly higher and positively correlated with serum levels in IBD patients under subcutaneous compared with intravenous infliximab maintenance therapy","volume":"13","author":"Roblin X","year":"2025","unstructured":"Roblin X, Nancey S, Duru G, et al. Tissue drug levels are significantly higher and positively correlated with serum levels in IBD patients under subcutaneous compared with intravenous infliximab maintenance therapy. United Eur Gastroenterol J 2025; 13: 1092.","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261461042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261461042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261461042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:47:11Z","timestamp":1784933231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261461042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":80,"alternative-id":["10.1177\/17562848261461042"],"URL":"https:\/\/doi.org\/10.1177\/17562848261461042","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261461042"}}